The first-leg tie takes place at Karađorđe Stadium in Novi Sad, Serbia, with kickoff scheduled for 20:00 CEST. Both clubs ...

Ever wonder if the Weapon X Affiliation could grow? Well here's a few sneaky options Atomic Mass Games could add to the list!

Ontario’s Quarter Horse Improvement Program committee (QHIP) is pleased to announce how it has allocated $500,000 in additional funding this year for the province’s Quarter Horse breeders and owners.

Britain’s Ajax armored vehicle was meant to replace outdated reconnaissance fleets and reshape the Army’s battlefield future.

The successful partnership between Ajax and the Sandals Foundation in Curaçao has resulted in the BBC documentary Future Goals, a short film about one of the most remarkable grassroots football ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

General Dynamics said the safety of soldiers 'is, and has always been, our highest priority'. Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister ...

Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister acknowledging more work is needed to "rebuild confidence" in the transportation. Testing of the ...

LONDON, April 28 (Reuters) - Britain's defence readiness minister Luke Pollard said he had agreed to restart the army's acceptance of Ajax armoured vehicles from General Dynamics with ‌strict controls ...

Eli Lilly LLY-2.33%decrease; down pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...